Fosun Pharma subsidiary gains drug approval for Foscarnet Sodium Injection

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. announced that its subsidiary, Guilin Pharmaceutical Co. Ltd., has received approval from the National Medical Products Administration for the drug registration of Foscarnet Sodium Injection. This injection is approved for treating cytomegalovirus retinitis in AIDS patients and acyclovir-resistant herpes simplex virus skin and mucous membrane infections in immunocompromised patients.

As of November 2025, the Group has invested approximately RMB4.98 million (unaudited) in the research and development of the drug. According to IQVIA CHPA data, sales of Foscarnet Sodium Injections in China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB86.40 million in 2024.

This approval is expected to further enrich Fosun Pharma's product line. However, the company cautions that actual sales performance post-market launch is subject to considerable uncertainty due to factors such as medication demand, market competition, and sales channels.